Our studies of the relationship between prolactin structure and function have resulted in the development of pure prolactin-receptor antagonists. These molecules prevent endogenous prolactin from ...

In a phase 2 trial, lusvertikimab significantly improves clinical and endoscopic outcomes in patients with moderate to severe ...

The addition of β-adrenergic receptor antagonists to a medical regimen for heart failure that includes angiotensin-converting enzyme (ACE) inhibitors as background therapy has been associated ...

Health technology is changing the way we treat pain. Orthokine Therapy uses the body’s own healing proteins to reduce ...

Receiving admilparant, an oral lysophosphatidic acid receptor 1 antagonist, for 26 weeks lowered percent-predicted FVC ...